We have found that HH-F3 treatment does significantly reduce the extracellular level of Aβ1-40 and Aβ1-42 in the normal lines too, as well as in the three AD-iN lines (Figs. 3b and 4b); furthermore, the treatment had a greater effect on the secretion of Aβ1-42 in iAPP(D678H) at lower dosages (Fig. 3b). The gene discussed is IAPP; the disease is Alzheimer disease.